On Thursday, Wall Street was higher in during the afternoon in trading; Apple, as well as biotech shares, spiked the market past the Federal Reserve meeting that will be taking place next week. Since China lowered the value of its currency in August, U.S. Stocks have been very sporadic Managing director at Beam Capital Management in New York, Mohannad Aama, said “Volatility is here to stay for the rest of the fourth quarter because even if the Fed doesn’t raise rates next week, it is signaling that there is weakness in the economy.” This volatility has also been very evident in penny stocks such as Progressive Care Inc. (OTCMKTS:RXMD), and others.
Progressive Care Inc (OTCMKTS:RXMD) provides prescription pharmaceuticals in South Florida and focus on health practice and risk management. The company saw an increase in trading volume after news was released on Thursday morning recording another record breaking month; the pharmacy recorded over 16,500 prescriptions in August. This accumulated to around $1.17 million in revenues. This is a 32% increase from just a year ago. Furthermore, this is the third month in a row of record-breaking prescription sales. The COO of the company, Shital Parikh Mars, said, “These last few months are a true testament to the hard work our staff puts in to market the Company and live up to the high standards of care that we set. We are leading the way in the level and range of services we provide and the South Florida community has embraced it.” RXMD over the last month has seen gains of 80.95% from lows of $0.0065 to highs of $0.0114.
High Performance Beverage Co. (OTCMKTS:TBEV) has also seen a rise in volume over the last couple of weeks. On Wednesday, the company announced a launch date of September 18, 2015 for their High Performance Sports Beverage. The company has made their own segment bit called “Throwdown Performance Beverages.” This segment produces a line of sport performance beverages made to sharpen mental focus and increase blood flow. By doing these two things, the body receives the fuel needed to get through an entire day, or just an event. The president of High Performance Beverage, Mike Holley, said “after speaking with Southeast Bottling we are confident that we will have the product out for shipping to our warehouse this Friday. We look forward to having our product in the hands of consumers within the next several days.” Over the last month, TBEV has been volatile with gains of 500% from lows of $0.0005 to highs of $0.003.
Axion Power International, Inc. (NASDAQ:AXPW) is another sporadic stock that specializes in technology. They design, manufacture, produce, and distribute advanced energy storage devices, components, and systems based on their very own PbC Technology. AXPW had a slow open at $1.59, but bounced 71.7% to a high of $2.73 in the afternoon at 1:10 PM. AXPW closed 45.05% higher than the open at $2.35. This is not the first time this week that AXPW has been volatile; in late August, the stock rose 273.78% from a low of $1.03 to a high of $3.85. Axion Power International Inc.’s monthly performance is up 5.890%.
mCig Inc (OTCMKTS:MCIG) is a top distributor of products, technologies, and services for both medicinal and recreational marijuana. On Thursday morning, mCig announced they signed an agreement with EmotekLabs, LLC. EmotekLabs is a Colorado-based company that develops award-winning commercial extractors. The partnership hopes to allow mCig to market the Emotek Cannapod and their line of extractors. Paul Rosenberg, CEO of mCig, Inc., stated, ”We are excited about the opportunity to work with Emotek and distribute their product to all legal zones around the world. The Emotek product line is a welcome addition to the portfolio of products mCig can offer.” This month, MCIG has seen a rise of 99.6% from $0.025 to $0.049.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.